Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Shoulder Innovations, Inc.NYSE: SI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows 471.7% year over year
Q1 FY2026 stock-based compensation of $726K rose 471.7% year over year. Sequentially, it rose 90.6% from the prior quarter.
Context
- Stock-based compensation amounted to 2.1% of revenue in FY2025, down 0.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 996K USD
- Year-over-year change
- +32.1%
- 2-year CAGR
- +48.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 996K | +32.1% |
| FY2024 | 2024-12-31 | 754K | +67.2% |
| FY2023 | 2023-12-31 | 451K | — |
Stock-Based Compensation vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 stock-based compensation of $1.6M is the 10th largest of the 11 companies compared; the peer median is $4.64M.
- Stock-based compensation amounts to 3.0% of revenue for SI, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.09M | -33.3% | -16.9% | 13.7% | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $7.82M | +9.7% | -13.3% | 2.2% | |
| LTM Mar 2026 | $6.04M | -48.6% | -13.0% | — | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| LTM Dec 2025 | $4.19M | -42.3% | -39.2% | 32.2% | |
| LTM Mar 2026 | $2.64M | +336.0% | +112.4% | — | |
| LTM Mar 2026 | $2.38M | -344.3% | — | 5.4% | |
| FY2025 | $2.21M | +28.2% | +36.6% | 2.0% | |
| LTM Mar 2026 | $1.6M | — | — | 3.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $1.44M | -63.8% | — | — |
| Peer median (excluding SI) | $4.64M | -33.1% | -12.3% | 7.1% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 451K | 754K | 996K |
| Change in Working Capital | (4.77M) | (1.04M) | 0 |
| Accounts Receivables | (2.69M) | (575K) | (3.3M) |
| Inventory | (2.41M) | (4.03M) | (7.64M) |
| Accounts Payables | (737K) | 3.12M | 3.37M |
| Other Working Capital | 1.08M | 446K | 0 |
| Other Non-Cash Items | 2.18M | (437K) | 7.54M |
| Operating Cash Flow | (13.14M) | (14.14M) | (28.61M) |
| Capital Expenditures | (2.75M) | (4.02M) | (7.41M) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (29.25M) | (5.28M) | (119.49M) |
| Sales of Investments | 3.03M | 23.26M | 31.3M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (28.97M) | 13.96M | (95.6M) |
| Debt Repayment | 10M | 0 | 0 |
| Common Stock Issued | 34.88M | 66K | 39.51M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (149K) | 66K | 144.96M |
| Financing Cash Flow | 44.73M | 66K | 144.96M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | 2.61M | (113K) | 20.75M |
| Free Cash Flow | (15.89M) | (18.16M) | (36.02M) |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.